CV Sciences Reports 11% Revenue Decline, Widened Net Loss in Q1 2026
CVSI sits 34% above its 52-week low of $0.023 on light trading volume (0.1× avg).
Summary
CV Sciences reported an 11.4% revenue drop and a wider net loss in Q1 2026, signaling ongoing financial challenges despite some operational improvements.
Key Events · Earnings and Guidance · CVSI
-
Revenue Decline
Q1 2026 revenue decreased 11.4% year-over-year to $3.2 million, primarily due to lower sales volume from restrictive regulations.
-
Widened GAAP Net Loss
The GAAP net loss significantly increased to $0.643 million in Q1 2026, compared to a loss of $0.109 million in Q1 2025.
-
Operational Improvements
Gross margin improved to 48.9% (from 46.0% in Q1 2025), and operating expenses were reduced by 13.3% to $1.9 million.
-
Adjusted EBITDA Loss Narrows
Adjusted EBITDA loss improved to $0.1 million in Q1 2026, compared to a loss of $0.3 million in Q1 2025.
Analysis · CVSI · Life Sciences
CV Sciences reported an 11.4% year-over-year revenue decline to $3.2 million and a significantly widened GAAP net loss of $0.643 million for Q1 2026. While the company showed some operational improvements, including a higher gross margin and reduced operating expenses, the overall financial results indicate continued challenges for this micro-cap company, which previously disclosed a going concern warning and has a very low cash balance. These results follow recent highly dilutive debt restructurings and a proposed reverse stock split.
At the time of this filing, CVSI was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.02 to $0.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.